Medication Management for Treatment-Resistant Bipolar Depression in Baltimore

man relaxing with coffee at a baltimore waterfront cafe feeling stable after medication management for treatment resistant bipolar depression in baltimore md

Bipolar depression can be among the most challenging conditions to treat because the goal is not simply to reduce depressive symptoms. Treatment must also account for a person’s history of mania, hypomania, mixed features, medication response, side effects, medical needs, and the risk that a poorly matched medication strategy could destabilize mood.

At Baltimore Ketamine Clinic, our medication-management approach is built around a careful review of the full clinical picture. For patients whose bipolar depression has not improved with prior treatment, the next step is not automatically adding another medication. It is understanding the diagnosis, reviewing what has already been tried, identifying safety concerns, and building a plan that reflects current evidence and the individual’s needs.

Why Bipolar Depression Requires a Different Medication Approach

Bipolar disorder involves shifts in mood, energy, activity, and concentration that can include depressive episodes as well as periods of mania or hypomania. The depressive phase can be especially difficult because symptoms may resemble unipolar major depression while requiring a different medication strategy.

A medication that may be appropriate for unipolar depression is not automatically appropriate for bipolar depression. In bipolar I disorder, antidepressant monotherapy is generally not recommended because it may increase the risk of mood switching or cycle destabilization in some patients. Antidepressants may still be considered in selected circumstances, but they require careful evaluation of the person’s bipolar subtype, prior response, current mood state, and concurrent mood-stabilizing treatment.

That is why a diagnosis review is so important. Before changing medications, clinicians need to understand whether a person has bipolar I disorder, bipolar II disorder, mixed symptoms, rapid cycling, co-occurring anxiety, substance-use concerns, trauma symptoms, or other factors that can affect treatment decisions.

For a broader overview of available care, visit our page on bipolar disorder treatment in Baltimore.

What “Treatment-Resistant” Means in Bipolar Depression

Treatment-resistant bipolar depression does not have one universally accepted definition. In general, it refers to a depressive episode that has not improved adequately after appropriate medication trials given at therapeutic doses, for a sufficient period of time, with reasonable adherence and diagnostic accuracy.

That definition matters because many people are told they have “failed” a medication when the trial was interrupted too early, the dose was not therapeutic, side effects were not addressed, or the medication did not match the actual diagnosis. Other patients have tried many medications over years and still have persistent symptoms despite careful treatment.

At Baltimore Ketamine Clinic, our approach to medication management for mental health begins with reviewing current symptoms, previous diagnoses, medical history, current medications, past medication trials, side effects, and treatment goals. We look at what was tried, how it was used, what happened, and what may still need to be clarified.

The goal is not to label someone as “too complex” or assume that all options have been exhausted. It is to create a more informed next step.

Guideline-Supported Medication Options

For acute bipolar I depression, guideline-supported first-line options include quetiapine, lithium, lamotrigine, and lurasidone. In some cases, these medications may be used alone; in others, combination treatment may be appropriate.

Each option has potential benefits and limitations:

Lithium may help with mood stabilization and can be an important option for some patients, but it requires ongoing laboratory monitoring and attention to kidney, thyroid, hydration, and medication-interaction considerations.

Lamotrigine may be helpful for some patients with bipolar depression, particularly when depressive symptoms are prominent, but it must be titrated gradually because of rare but serious rash risk.

Quetiapine and lurasidone are among the medications with evidence for bipolar depression, though each has its own side-effect profile and monitoring needs.

Other medication strategies may be considered when first-line options have not provided enough relief or are not well tolerated.

Medication management is not only about choosing an agent. It also involves monitoring sleep, energy, anxiety, agitation, mood elevation, depressive symptoms, side effects, physical health, and functional changes over time.

Why a Detailed Medication History Matters

Many patients with treatment-resistant bipolar depression arrive with a long list of prior medications. That history can feel discouraging, especially after partial improvement, difficult side effects, or symptoms that return after an initial response.

A detailed medication review can help answer important questions:

Was the original diagnosis complete and accurate? Were prior medication trials given an adequate dose and duration? Did a medication help one symptom while worsening another? Were there signs of mania, hypomania, mixed features, or rapid cycling? Are current medications interacting in ways that affect mood, sleep, or safety? Is there an evidence-based option that has not yet been considered? Would psychotherapy, sleep support, substance-use treatment, or another service strengthen the overall plan?

Medication changes should not be made abruptly or without prescriber guidance. For people with bipolar disorder, sudden medication changes can increase the risk of withdrawal effects, relapse, mood instability, or other complications. Our post on ketamine for bipolar disorder: exploring a new frontier provides additional context on emerging research in this area.

The Role of Ketamine in Bipolar Depression

Ketamine is not a first-line treatment for bipolar depression. It is used off-label for psychiatric conditions, and the evidence for bipolar depression remains preliminary.

Small controlled studies, systematic reviews, and real-world clinical reports suggest that intravenous ketamine may reduce depressive symptoms for some patients with treatment-resistant bipolar depression. However, available studies are limited by small samples, varied treatment protocols, and short follow-up periods. They do not establish ketamine as a standard treatment for bipolar disorder or as a substitute for evidence-based mood-stabilizing medication.

Mood switching, hypomania, and mania remain important safety considerations in bipolar disorder. Early studies have not consistently shown high rates of switching during acute ketamine treatment, but current evidence does not eliminate the need for careful screening, ongoing monitoring, and individualized risk assessment. Ketamine is not appropriate during active mania or psychosis.

For selected patients, ketamine treatment in Baltimore may be discussed after a comprehensive psychiatric evaluation. Patients who want to understand what the process looks like can also review our complete overview of the ketamine infusion process.

SPRAVATO® and Bipolar Depression

SPRAVATO® is an FDA-approved esketamine nasal spray for adults with treatment-resistant depression and for depressive symptoms in adults with major depressive disorder and acute suicidal ideation or behavior. It is not FDA-approved or indicated for bipolar depression.

Research in bipolar depression is limited, and the original approval studies did not establish SPRAVATO® as a treatment for bipolar disorder. The clinic’s SPRAVATO® screening guidance also identifies bipolar disorder as a contraindication. For that reason, SPRAVATO® is not an appropriate treatment pathway for bipolar depression at Baltimore Ketamine Clinic.

Medication Management Is Ongoing Care

Bipolar depression rarely improves through one appointment or one medication adjustment. Effective medication management is an ongoing process that includes follow-up, symptom monitoring, safety review, and open discussion about what is and is not working.

For some patients, that may mean optimizing a first-line medication. For others, it may mean addressing an incomplete diagnosis, reducing problematic side effects, reconsidering an antidepressant strategy, or incorporating psychotherapy and additional support.

When appropriate and with patient permission, coordination with an existing psychiatrist, therapist, primary-care clinician, or other treatment provider can help create a more consistent plan. Patients should bring a complete medication list, prior records when available, and information about past treatment response to their first appointment.

FAQ

What makes bipolar depression different from unipolar depression?

Bipolar depression occurs in the context of bipolar disorder, which includes a history of mania or hypomania. Treatment decisions must account for the possibility of mood switching, mixed symptoms, and the need for mood stabilization. This makes medication management more complex than treating unipolar major depression alone.

How do I know whether my bipolar depression is treatment-resistant?

Treatment resistance generally means depressive symptoms have not improved enough after appropriate medication trials. A thorough review should consider diagnosis, medication dose, duration, adherence, side effects, prior response, co-occurring conditions, and whether first-line options were adequately tried.

Are antidepressants safe for bipolar depression?

Antidepressants can be appropriate in selected situations, but they require careful prescribing and monitoring. Antidepressant monotherapy is generally not recommended for bipolar I depression because of the potential risk of mania, hypomania, or cycle destabilization.

Can ketamine be used for bipolar depression?

Ketamine has been studied off-label in treatment-resistant bipolar depression, but the evidence remains limited. It is not a first-line treatment and should be considered only after a comprehensive evaluation of diagnosis, treatment history, medical safety, and mood-switching risk. Ketamine is not appropriate during active mania or psychosis.

Is SPRAVATO® approved for bipolar depression?

No. SPRAVATO® is FDA-approved for specific forms of major depressive disorder, not bipolar depression. Baltimore Ketamine Clinic does not consider SPRAVATO® an appropriate treatment pathway for bipolar depression.

What should I bring to a medication-management appointment?

Bring a list of all current and previous medications, including doses, approximate dates, side effects, and whether each medication helped. Previous psychiatric records, hospital-discharge summaries, laboratory results, and information about current providers can also be useful.

Key Takeaways

Bipolar depression requires a different medication approach than unipolar major depression. Accurate diagnosis is essential because bipolar I disorder, bipolar II disorder, mixed features, and rapid cycling can affect treatment choices. Treatment-resistant bipolar depression usually involves inadequate improvement after appropriate medication trials, but each prior trial should be reviewed carefully. First-line treatment options for acute bipolar I depression include quetiapine, lithium, lamotrigine, and lurasidone. Antidepressant monotherapy is generally not recommended for bipolar I depression. Ketamine is used off-label for bipolar depression, and current evidence remains preliminary. Ketamine is not appropriate during active mania or psychosis. SPRAVATO® is not FDA-approved or indicated for bipolar depression and is not an appropriate treatment pathway for bipolar depression at Baltimore Ketamine Clinic. Ongoing medication management should include careful monitoring, individualized planning, and appropriate coordination of care.

Conclusion

Bipolar depression deserves specialized attention, especially when symptoms have persisted despite previous medication treatment. Feeling discouraged after multiple medication trials is understandable, but it does not mean there are no remaining options to explore.

At Baltimore Ketamine Clinic, we approach treatment-resistant bipolar depression with careful diagnostic review, evidence-informed medication management, and realistic discussion about available treatments. For people in Baltimore who are living with persistent bipolar depression, a comprehensive evaluation can help clarify the safest and most appropriate next step. To get started, schedule a consultation with our team today.

About Ivana Mitic

Ivana Mitic, CRNA, PMHNP, is the founder of Baltimore Ketamine Clinic. She brings training in anesthesiology and psychiatric mental-health care to the evaluation and treatment of patients with depression, anxiety, PTSD, OCD, and other treatment-resistant mental-health concerns. Her approach emphasizes individualized assessment, medication safety, and compassionate care.

Works Cited

National Institute of Mental Health. (2024). Bipolar disorder. https://www.nimh.nih.gov/health/topics/bipolar-disorder

Keramatian, K., Chithra, N. K., & Yatham, L. N. (2023). The CANMAT and ISBD guidelines for the treatment of bipolar disorder: Summary and a 2023 update of evidence. Focus, 21(4), 344–353. https://pubmed.ncbi.nlm.nih.gov/38695002/

Vieta, E., et al. (2025). Defining treatment-resistant bipolar depression. Bipolar Disorders. https://pubmed.ncbi.nlm.nih.gov/40808269/

Fancy, F., et al. (2023). Ketamine for bipolar depression: An updated systematic review. Therapeutic Advances in Psychopharmacology, 13. https://pubmed.ncbi.nlm.nih.gov/37771417/

Santucci, M. C., Ansari, M., Nikayin, S., et al. (2024). Efficacy and safety of ketamine/esketamine in bipolar depression in a clinical setting. Journal of Clinical Psychiatry, 85(4), 24m15376. https://pubmed.ncbi.nlm.nih.gov/39361411/

U.S. Food and Drug Administration. (2025). SPRAVATO® (esketamine) nasal spray prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/211243s016lbl.pdf

Medical Disclaimer

The information provided in this blog is for educational purposes only and does not constitute medical advice. Ketamine is used off-label for psychiatric indications, including bipolar depression. SPRAVATO® is not FDA-approved for bipolar depression. Treatment outcomes vary by individual. Please consult with a qualified healthcare provider before beginning or changing any treatment plan. In an emergency, call 911 or seek immediate emergency care.

Share Now :